These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39050978)

  • 41. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Manyam BV; Garsa AA; Chin RI; Reddy CA; Gastman B; Thorstad W; Yom SS; Nussenbaum B; Wang SJ; Vidimos AT; Koyfman SA
    Cancer; 2017 Jun; 123(11):2054-2060. PubMed ID: 28171708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
    Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
    Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ
    ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
    Mallardo D; Simeone E; Festino L; Tuffanelli M; Vanella V; Trojaniello C; Vitale MG; Ottaviano M; Capone M; Madonna G; Sparano F; Cioli E; Scarpato L; Palla M; Di Trolio R; Meinardi P; Caracò C; Ferrara G; Muto P; Cavalcanti E; Ascierto PA
    J Transl Med; 2023 Feb; 21(1):140. PubMed ID: 36823670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
    Mager L; Gardeen S; Carr DR; Shahwan KT
    Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
    Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
    Front Oncol; 2021; 11():691980. PubMed ID: 34540666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
    Black CM; Hanna GJ; Wang L; Ramakrishnan K; Goto D; Turzhitsky V; Hair GM
    Front Oncol; 2023; 13():1160144. PubMed ID: 37284189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cemiplimab in advanced cutaneous squamous cell carcinoma.
    Naik PP
    Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
    Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
    Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
    [No Abstract]   [Full Text] [Related]  

  • 53. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion.
    Argenziano G; Fargnoli MC; Fantini F; Gattoni M; Gualdi G; Pastore F; Pellacani G; Quaglino P; Queirolo P; Troiani T
    Ther Adv Med Oncol; 2022; 14():17588359211066272. PubMed ID: 35035534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer.
    Nguyen JH; Epling D; Dolphin N; Paccaly A; Conrado D; Davis JD; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1458-1471. PubMed ID: 36251220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
    Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
    Lee A; Duggan S; Deeks ED
    Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.
    Shah NJ; Sura SD; Shinde R; Shi J; Singhal PK; Robert NJ; Vogelzang NJ; Perini RF; Motzer RJ
    Eur Urol Open Sci; 2023 Mar; 49():110-118. PubMed ID: 36874600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
    Mallardo D; Sparano F; Vitale MG; Trojaniello C; Fordellone M; Cioli E; Esposito A; Festino L; Mallardo M; Vanella V; Facchini BA; De Filippi R; Meinardi P; Ottaviano M; Caracò C; Simeone E; Ascierto PA
    Cancer Immunol Immunother; 2024 Jun; 73(8):160. PubMed ID: 38850335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
    Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation.
    Potestio L; Scalvenzi M; Lallas A; Martora F; Guerriero L; Fornaro L; Marano L; Villani A
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.